Matured DCs acquire enhanced antigen cross-presentation ability [47–49] and then secrete multiple proinflammatory cytokines, including interleukin 6 (IL-6), including interleukin 12 (IL-12), and tumour necrosis factor α (TNF-α), regulating antitumour immune responses [50], which facilitates the activation of CTLs (cytotoxic T lymphocytes) to eradicate tumours [51]. The gene discussed is IL6; the disease is neoplasm.